My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR)
- PMID: 26183166
- PMCID: PMC4592416
- DOI: 10.1177/0272989X15594382
My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR)
Abstract
Background: Decision-making experts emphasize that understanding and using probabilistic information are important for making informed decisions about medical treatments involving complex risk-benefit tradeoffs. Yet empirical research demonstrates that individuals may not use probabilities when making decisions.
Objectives: To explore decision making and the use of probabilities for decision making from the perspective of women who were risk-eligible to enroll in the Study of Tamoxifen and Raloxifene (STAR).
Methods: We conducted narrative interviews with 20 women who agreed to participate in STAR and 20 women who declined. The project was based on a narrative approach. Analysis included the development of summaries of each narrative, and thematic analysis with developing a coding scheme inductively to code all transcripts to identify emerging themes.
Results: Interviewees explained and embedded their STAR decisions within experiences encountered throughout their lives. Such lived experiences included but were not limited to breast cancer family history, a personal history of breast biopsies, and experiences or assumptions about taking tamoxifen or medicines more generally.
Conclusions: Women's explanations of their decisions about participating in a breast cancer chemoprevention trial were more complex than decision strategies that rely solely on a quantitative risk-benefit analysis of probabilities derived from populations In addition to precise risk information, clinicians and risk communicators should recognize the importance and legitimacy of lived experience in individual decision making.
Keywords: breast cancer risk; chemoprevention; decision making; individualized risk information; lived experiences; narrative interviews.
© The Author(s) 2015.
Figures
Similar articles
-
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.J Clin Oncol. 2002 Aug 1;20(15):3328-43. doi: 10.1200/JCO.2002.06.029. J Clin Oncol. 2002. PMID: 12149307 Review.
-
Women's decision making about whether or not to use breast cancer chemoprevention.Women Health. 2005;41(2):81-95. doi: 10.1300/J013v41n02_06. Women Health. 2005. PMID: 16219589
-
Breast cancer prevention trials.Curr Oncol Rep. 2000 Nov;2(6):558-65. doi: 10.1007/s11912-000-0110-0. Curr Oncol Rep. 2000. PMID: 11122893 Review.
-
Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.Cancer Prev Res (Phila). 2019 Nov;12(11):801-808. doi: 10.1158/1940-6207.CAPR-19-0021. Epub 2019 Aug 20. Cancer Prev Res (Phila). 2019. PMID: 31431499 Free PMC article.
-
What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?Patient. 2016 Apr;9(2):149-59. doi: 10.1007/s40271-015-0134-z. Patient. 2016. PMID: 26115846 Free PMC article.
Cited by
-
Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors.Am J Med. 2020 Jun;133(6):723-732. doi: 10.1016/j.amjmed.2019.11.017. Epub 2019 Dec 17. Am J Med. 2020. PMID: 31862335 Free PMC article.
-
Talking numbers: how women and providers use risk scores during and after risk counseling - a qualitative investigation from the NRG Oncology/NSABP DMP-1 study.BMJ Open. 2023 Nov 19;13(11):e073138. doi: 10.1136/bmjopen-2023-073138. BMJ Open. 2023. PMID: 37984961 Free PMC article. Clinical Trial.
-
Physician and Patient Barriers to Breast Cancer Preventive Therapy.Curr Breast Cancer Rep. 2016;8(3):158-164. doi: 10.1007/s12609-016-0216-5. Epub 2016 Jun 13. Curr Breast Cancer Rep. 2016. PMID: 27617055 Free PMC article. Review.
-
Effect of a Website That Presents Patients' Experiences on Self-Efficacy and Patient Competence of Colorectal Cancer Patients: Web-Based Randomized Controlled Trial.J Med Internet Res. 2017 Oct 13;19(10):e334. doi: 10.2196/jmir.7639. J Med Internet Res. 2017. PMID: 29030329 Free PMC article. Clinical Trial.
-
Understanding participation in European cohort studies of preterm children: the views of parents, healthcare professionals and researchers.BMC Med Res Methodol. 2021 Jan 12;21(1):19. doi: 10.1186/s12874-020-01206-5. BMC Med Res Methodol. 2021. PMID: 33430773 Free PMC article.
References
-
- Zikmund-Fisher BJ. The right tool is what they need, not what we have: a taxonomy of appropriate levels of precision in patient risk communication. Medical care research and review : MCRR. 2013 Feb;70(1 Suppl):37S–49S. - PubMed
-
- Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103(10):1996–2005. - PubMed
-
- Waters EA, Weinstein ND, Colditz GA, Emmons K. Aversion to side effects in preventive medical treatment decisions. British Journal of Health Psychology. 2007;12:383–401. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical